Kalciumpyrofosfatdeposition
Pseudogout
Granskad av Dr Toni Hazell, FRCGPSenast uppdaterad av Dr Philippa Vincent, MRCGPSenast uppdaterad 30 jun 2026
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
Medicinska yrkesverksamma
Professionella referensartiklar är utformade för att användas av vårdpersonal. De är skrivna av brittiska läkare och baserade på forskningsbevis, brittiska och europeiska riktlinjer. Du kan hitta Kalciumpyrofosfatdeposition artikel mer användbar, eller en av våra andra hälsoartiklar.
Bakgrund12
Previously known as pseudogout, calcium pyrophosphate deposition disease (CPPD) is an inflammation of joints caused by the deposition of calcium pyrophosphate (CPP) crystals in articular and periarticular tissues.
Epidemiologi34
Calcium pyrophosphate deposition is common in the elderly. Half of adults develop radiographic changes typical of CPPD by the age of 80.
30-50% of patients with CPPD are over the age of 85.4
Most cases of CPPD are non-familial but mutations in the ANK human gene (ANKH) have been demonstrated in some families.5
Due to the low sensitivity of conventional radiography, it is likely that the prevalence of CPPD is underestimated.
Uttorkning.
Intercurrent illness.
Previous surgery or trauma to the joint.
A history of gout.
Family history of CPPD.
Artros.
Primary hyperparathyroidism.
Hemokromatos.
Hypophosphatasia.
Hypomagnesaemia.
Presentation34
CPPD is often asymptomatic, with only radiographic changes of chondrocalcinosis.
Calcium pyrophosphate deposition may cause an acute or chronic arthritis:
Acute CPP crystal arthritis (or pseudogout):
Acute onset of monoarticular or oligoarticular arthritis.
The knee is the most commonly involved joint, followed by the wrist.
Acute attacks of CPPD disease usually settle within 10 days but may last for weeks or months.
Systemic symptoms including fevers, and chills, and constitutional symptoms may occur.
Chronic CPP crystal arthritis:
Most affected patients have a polyarticular form of arthritis that resembles osteoarthritis, but with flares of inflammatory signs and symptoms and by unusually severe articular damage. Involvement of joints such as the glenohumeral joint, wrist, and metacarpophalangeal joints, which are not often affected by typical osteoarthritis, should lead one to suspect CPPD disease.
A rarer form of polyarticular CPPD disease resembles rheumatoid arthritis, with persistent inflammatory arthritis that affects large and small joints. Flares often involve joints sequentially, and involvement is less symmetric than that seen with rheumatoid arthritis.
Differentialdiagnos
Utredningar38
Plain x-ray, ultrasound, CT scan and DECT scans can all be used in the diagnosis of CPPD.
Crystals can be identified on aspiration of the joint fluid.
Ledning8910 11
Unlike gout, there are no specific disease-modifying treatments for the elimination of CPP crystals from the body. Treatment is therefore largely symptomatic, as well as ensuring good management of any underlying metabolic conditions. Care should be tailored to individual patients and should take account of any comorbidities and existing medication regimes.
The European guidelines advice the use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids (intra-articular or systemic). The drug of choice will depend on the patient's age and comorbidities.
In 2023, a large study supported the use of prednisolone 30 mg a day as the first line treatment for CPPD. If colchicine is used, initiation in the first 12 hours of symptoms is important.
For chronic CPP crystal arthritis:
Daily colchicine is the preferred first-line treatment, whereas methotrexate and tocilizumab are considered second-line options.47
For patients with monoarticular or oligoarticular large-joint involvement, repeated intra-articular injections of glucocorticoids may control symptoms.
Prognos4
Acute attacks often resolve within ten days.
However some acute attacks may last for weeks or months.
Some patients develop progressive joint damage with functional limitation.
Chronic CPPD is characterised by recurrent flare-ups, with symptoms that frequently overlap those of rheumatoid arthritis.
Prognosis will also be dependent on any underlying cause.
Exklusiva uppdateringar för vårdpersonal
Håll dig informerad med de senaste kliniska uppdateringarna, professionella insikter och evidensbaserad vägledning. Patient Pro-nyhetsbrevet sammanställer viktigt innehåll för vårdpersonal—levererat direkt till din inkorg.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.
Vidare läsning och referenser
- Rosenthal AK, Ryan LM; Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016 Jun 30;374(26):2575-84. doi: 10.1056/NEJMra1511117.
- Pseudogout, chondrocalcinosis, CPPD et al: crystal clear… or clear as mud?–The time has come to reconsider the nomenclature of calcium pyrophosphate deposition; S Sirotti et al; Annals of the Rheumatic Diseases
- EULAR recommendations for calcium pyrophosphate deposition - Part I: terminology and diagnosis; European League Against Rheumatism (2011)
- Azam A, Minalyan A, Naik R; Calcium Pyrophosphate Deposition Disease.
- Tsui FW; Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2012 Apr;14(2):155-60. doi: 10.1007/s11926-011-0230-6.
- Calcium pyrophosphate deposition disease: The arthropathy formerly known as “Pseudogout”; BPAC NZ
- Calcium pyrophosphate deposition disease; Prof T Pascar et al; The Lancet
- Calcium pyrophosphate dihydrate deposition disease; R Sharma; Radiopedia
- EULAR recommendations for calcium pyrophosphate deposition - Part II Management; European League Against Rheumatism (2011)
- Recent advances in the therapeutic management of calcium pyrophosphate deposition disease; P Voulgari et al; Frontiers in Medicine
- Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review; S Cowley and G McCarthy; Open Access Rheumatology: Research and Reviews
Om recensentenVisa fullständig biografi

Dr Toni Hazell, FRCGP
MBBS, BSc, FRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)
Dr. Toni Hazell tog examen från St. Mary’s Hospital Medical School och genomförde sin VTS vid Northwick Park Hospital.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
Next review due: 29 Dec 2030
30 jun 2026 | Senaste versionen
Mer inom reumatologi
- Värkande leder - bedömning, undersökningar och hantering i primärvården
- Ankyloserande spondylit
- Anti-tumörnekrosfaktor alfa
- UppdateradBedömning av patienten med etablerad diabetes
- Bakers cysta
- Enteropatisk artrit
- Eosinofili-myalgisyndrom
- Jättecellsarterit
- Knäledsproteser
- Knäsmärta
- Limb-gördel muskeldystrofi
- Blandad bindvävssjukdom
- Artros
- Polymyalgia reumatika
- Prepatellär bursit
- Psoriasisartrit
- Severs sjukdom
- Axelledsproteser
- Axelsmärta
- Sjögrens syndrom


